Please wait while we load the requested 20-F report or click the link below:
https://last10k.com/sec-filings/report/353278/000120864614000046/c109473_20f.htm
June 2023
May 2023
May 2023
May 2023
May 2023
May 2023
May 2023
May 2023
May 2023
May 2023
Please wait while we load the requested 20-F report or click the link below:
https://last10k.com/sec-filings/report/353278/000120864614000046/c109473_20f.htm
Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Novo Nordisk A S.
Novo Nordisk A S's Definitive Proxy Statement (Form DEF 14A) filed after their 2014 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Novo Nordisk A S provided additional information to their SEC Filing as exhibits
Ticker: NVO
CIK: 353278
Form Type: 20-F Annual Report
Accession Number: 0001208646-14-000046
Submitted to the SEC: Wed Feb 05 2014 10:10:27 AM EST
Accepted by the SEC: Wed Feb 05 2014
Period: Tuesday, December 31, 2013
Industry: Pharmaceutical Preparations